Saeed Dabestani
Overview
Explore the profile of Saeed Dabestani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
3419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bedke J, Ghanem Y, Albiges L, Bonn S, Campi R, Capitanio U, et al.
Eur Urol
. 2025 Feb;
PMID: 39904712
The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell...
2.
Sakalis V, Bhattacharya Y, Beyer K, Murray C, Smith E, Willemse P, et al.
Eur Urol Open Sci
. 2024 Nov;
70:183-193.
PMID: 39611162
Background And Objective: Clinical practice guidelines for prostate cancer (PCa) are a valuable resource for everyday clinical practice. The clinical practice guidelines and recommendations produced by various societies should demonstrate...
3.
Azawi N, Mosholt K, Fryd N, Lund L, Brignone J, Hvid N, et al.
BMC Urol
. 2023 Oct;
23(1):168.
PMID: 37875832
Background: Plasma soluble urokinase-type Plasminogen Activator Receptor (suPAR) predicts disease aggressiveness in renal cell carcinoma (ccRCC), but its prognostic accuracy has not been investigated. To investigate the prognostic accuracy of...
4.
Zumstein V, Parsons B, Dabestani S, Baranowski A, Tidman V, Berghmans B, et al.
Eur Urol Open Sci
. 2023 Sep;
56:29-38.
PMID: 37711669
Context: Radiotherapy of the pelvis is a widely used method for the treatment of malignancies, and local complications including pain following pelvic radiation therapy are acknowledged complications. Objective: The primary...
5.
MacLennan S, Wintner L, Beyer K, Lawlor A, Tripathee S, Dabestani S, et al.
BJUI Compass
. 2023 Aug;
4(5):504-512.
PMID: 37636213
Background: There is inconsistency in outcomes collected in renal cell cancer (RCC) intervention effectiveness studies and variability in their definitions. This makes critical summaries of the evidence base difficult and...
6.
Azawi N, Tolouee S, Dabestani S
Scand J Urol
. 2023 Jan;
57(1-6):81-85.
PMID: 36703546
Objective: To report the risk of venous thromboembolism (VTE) after partial nephrectomy in Denmark. Materials And Methods: A nationwide population-based registry was used to conduct a retrospective cohort study. All...
7.
Marconi L, Kuusk T, Capitanio U, Beisland C, Lam T, Pello S, et al.
Eur Urol Open Sci
. 2023 Jan;
47:65-72.
PMID: 36601038
Background: Retrospective comparative studies suggest a survival benefit after complete local treatment of recurrence (LTR) in renal cell carcinoma (RCC), which may be largely due to an indication bias. Objective:...
8.
Beyer K, Widdershoven C, Wintner L, Dabestani S, Marconi L, Moss C, et al.
Eur Urol Open Sci
. 2022 Dec;
48:1-11.
PMID: 36578462
Context: Outcomes in renal cell carcinoma (RCC) are reported inconsistently, with variability in definitions and measurement. Hence, it is difficult to compare intervention effectiveness and synthesise outcomes for systematic reviews...
9.
Capitanio U, Bedke J, Albiges L, Volpe A, Giles R, Hora M, et al.
Eur Urol
. 2022 Dec;
83(3):e74-e75.
PMID: 36526491
No abstract available.
10.
Bedke J, Albiges L, Capitanio U, Giles R, Hora M, Ljungberg B, et al.
Eur Urol
. 2022 Dec;
83(1):10-14.
PMID: 36511268
In KEYNOTE-564, adjuvant pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) in localised clear-cell renal cell carcinoma (ccRCC) with a high risk of relapse. In 2021, the European Association...